Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593049 | 1.00 | L3MBTL1 (0.33) | L3MBTL1TDP1POLBNPSR1PDPK1 | |
| SCHEMBL26068373 | 0.86 | MEN1 (0.34) | L3MBTL1TDP1POLBNPSR1PDPK1 | |
| SCHEMBL19730138 | 0.86 | TDP1 (0.33) | L3MBTL1TDP1POLBNPSR1PDPK1 | |
| SCHEMBL19730149 | 0.86 | L3MBTL1 (0.36) | L3MBTL1TDP1POLBNPSR1PDPK1 | |
| SCHEMBL19730137 | 0.85 | L3MBTL1 (0.33) | L3MBTL1TDP1POLBNPSR1PDPK1 | |
| SCHEMBL13505462 | 0.80 | PDPK1 (0.38) | L3MBTL1TDP1POLBNPSR1PDPK1 | |
| SCHEMBL29863128 | 0.80 | PDPK1 (0.38) | L3MBTL1TDP1POLBNPSR1PDPK1 | |
| SCHEMBL19730148 | 0.80 | CACNA1G (0.35) | L3MBTL1TDP1POLBNPSR1PDPK1 | |
| SCHEMBL30002876 | 0.77 | JAK1 (0.39) | PDPK1MEN1KMT2A | |
| SCHEMBL22939319 | 0.76 | SYK (0.39) | L3MBTL1TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370208-B2 | Adenosine derivative and pharmaceutical composition comprising the same | BRII BIOSCIENCES, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20230226093-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BRII BIOSCIENCES, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226093-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BRII BIOSCIENCES, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20220288098-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BRII BIOSCIENCES, INC. | 2022-09-15 | — | — | US | disclosed |
| US-20220048912-A1 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-17 | — | — | US | disclosed |
| EP-3894394-A1 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen BioPharma, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020121122-A1 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Biopharma, Inc. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9650342-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2017-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226093-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ADAR, ADA, ADORA2A | L3MBTL1 1456/4885TDP1 170/4885POLB 99/4885 |
| US-12370208-B2 | Adenosine derivative and pharmaceutical composition comprising the same | ADAR, ADA, ADORA2A | L3MBTL1 1456/4885TDP1 170/4885POLB 99/4885 |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | ADCY1, ADCY2, ADCY5 | L3MBTL1 2316/4885TDP1 1462/4885POLB 3528/4885 |
| US-20220048912-A1 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | TYMP, POLB, HMBS | L3MBTL1 3182/4885TDP1 1216/4885POLB 2/4885 |
| US-20220288098-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ADAR, ADA, ADORA2A | L3MBTL1 1456/4885TDP1 170/4885POLB 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.